TickerHumSide-by-side comparison
AbbVie vs Regeneron Pharmaceuticals
As of Nov 11, 2026, P/E is 50.8x for AbbVie vs 21.2x for Regeneron Pharmaceuticals; revenue growth is 10.7% for AbbVie vs 18.6% for Regeneron Pharmaceuticals; operating margin is 32.2% for AbbVie vs 28.8% for Regeneron Pharmaceuticals; net margin is 15.7% for AbbVie vs 28.5% for Regeneron Pharmaceuticals.
What stands out
- Regeneron Pharmaceuticals is cheaper on earnings: 21.2x P/E vs 50.8x for AbbVie.
- Regeneron Pharmaceuticals scores higher on TickerHum's ratings: 79/100 vs 63/100 for AbbVie.
Key metrics
| Metric | ABBV | REGN |
|---|---|---|
| Price | $294.98 | $959.41 |
| Market cap | $521.41B | — |
| P/E | 50.8x (#2) | 21.2x (#1) |
| P/S | 7.9x (#1) | — |
| Revenue growth | 10.7% (#2) | 18.6% (#1) |
| Operating margin | 32.2% (#1) | 28.8% (#2) |
| Net margin | 15.7% (#2) | 28.5% (#1) |
| Debt / equity | — | 0.06 (#1) |
| 1-year return | +26.5% (#2) | +40.7% (#1) |
| Research score | 63/100 (#2) | 79/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Regeneron Pharmaceuticals, Inc. (REGN) — Biotechnology